Effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients.
Neverov
N I
NI
Moscow Medical Academy, Russia.
Kaysen
G A
GA
Tareyeva
I E
IE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D018752:Diet, Fat-Restricted; D018450:Disease Progression; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006949:Hyperlipidemias / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D006973:Hypertension / Q000150:complications; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000628:therapy
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D002784:Cholesterol; D008148:Lovastatin; D003404:Creatinine